LEAS

ANEW MEDICAL ANNOUNCES KEY PATENT ISSUED IN CHINA TO PROTECT KLOTHO PROTEIN AND GENE DELIVERY SYSTEMS

Retrieved on: 
Monday, March 4, 2024
CFO, Acquisition, Ageing, ICREA, LEAS, Memory, Patent, Cognition, UAB

NEW YORK, March 4, 2024 /PRNewswire/ -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (OTCPK: LEAS) a US-based biotechnology company ("ANEW") focused on developing cell and gene- based treatments to affect aging and age-related diseases, announced that is has been granted and issued a patent in China, number CN 117126829 A for the use of ANEW's Klotho protein and Klotho gene delivery and expression systems in the treatment of cognition, memory and neurodegenerative diseases.

Key Points: 
  • NEW YORK, March 4, 2024 /PRNewswire/ -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (OTCPK: LEAS) a US-based biotechnology company ("ANEW") focused on developing cell and gene- based treatments to affect aging and age-related diseases, announced that is has been granted and issued a patent in China, number CN 117126829 A for the use of ANEW's Klotho protein and Klotho gene delivery and expression systems in the treatment of cognition, memory and neurodegenerative diseases.
  • Dr. Joseph Sinkule, the Founder and CEO of ANEW stated "Obtaining a patent in China was difficult but important to our global product development programs in neurodegenerative diseases.
  • The aging population in China is affected by the same age-related diseases we are fighting in the US and Europe.
  • In May 2023, ANEW announced its proposed merger with a special purpose acquisition company ("SPAC") called Redwoods (NASDAQ: RWOD) ("RWOD" or "Redwoods").

ANEW MEDICAL, INC. (OTC: LEAS) and Redwoods Acquisition Corp. (NASDAQ: RWOD) Entered into a Definitive Merger Agreement

Retrieved on: 
Tuesday, June 6, 2023
Cognition, SPAC, LEAS, Partnership, Drug development, OTC Markets Group, Acquisition, Parkinson's disease, Patent, OTC, Growth, ALS, Memory, Alzheimer's disease, Pharmaceutical industry, Sequoioideae

ANEW MEDICAL is developing a platform and commercializing novel gene therapies to alleviate and/or reverse the progression of neurodegenerative diseases.

Key Points: 
  • ANEW MEDICAL is developing a platform and commercializing novel gene therapies to alleviate and/or reverse the progression of neurodegenerative diseases.
  • NEW YORK, June 6, 2023 /PRNewswire/ -- ANEW MEDICAL, INC. (OTC: LEAS), an early-stage biotechnology company focused on developing disruptive new therapies to treat age-related neurodegenerative diseases, previously announced that it has entered into a definitive business combination agreement with Redwoods Acquisition Corp. (NASDAQ: RWOD; "Redwoods"), a publicly traded special purpose acquisition company, or SPAC.
  • ANEW MEDICAL (ANEW) currently has its common stock quoted on the OTC Markets under the symbol "LEAS".
  • ANEW has other patents pending issuance in the US, and patent applications that have not yet been examined.

Gene therapy candidate for amyotrophic lateral sclerosis (ALS) demonstrates bioactivities in a murine model of the disease

Retrieved on: 
Monday, March 13, 2023
Friedreich's ataxia, Respiratory failure, CNS, Muscular dystrophy, Animal, Cell, Sporadic group, Spinal cord, Atrophy, SOD1, Excitotoxicity, OTC, LEAS, ALS, Multiple sclerosis, Gene, AAV, Death, Nervous system, Brain cell, Oxidative stress, Rare, RNA, Risk, Muscle atrophy, Multimedia, European Society of Gene and Cell Therapy, Facial muscles, DNA, Myasthenia gravis, Denervation, DSM-IV codes, Diagnosis, Neuropathology, Tetraplegia, Messenger, Nerve, Drug Quality and Security Act, Therapy, The Company, Human, FINRA, Cancer, Motor cortex, Survival, Patient, Vaccine, Dietary supplement

Thus, long-term supplementation of the s-KL protein via gene therapy technology is an attract new measure for treatment of this deadly disease.

Key Points: 
  • Thus, long-term supplementation of the s-KL protein via gene therapy technology is an attract new measure for treatment of this deadly disease.
  • The technology was licensed on an exclusive worldwide basis from the Universitat Autonomo de Barcelona in Barcelona, Spain.
  • The overexpression of the SOD1 gene in humans is called "familial ALS" and occurs in 5%-10% of all ALS cases.
  • The delivery and expression of the s-KL protein by the s-KL gene may be an effective therapy in this degenerative neuromuscular disease" said Dr. Sinkule.

ANEW MEDICAL Licenses Melanocortin Receptor-binding Peptides for Pharmaceutical Development

Retrieved on: 
Tuesday, February 14, 2023
DNA, MC1R, University of Arizona, Life, Hormone, Melanoma, Therapy, LEAS, Skin cancer, Pigment, Acquisition, Skin, RNA, University, UV, Peptide, Radiation, Risk, Drug Quality and Security Act, Cancer, Fine chemical

Companies like Clinuvel and Palatin have commercialized medical products using alpha-melanocortin stimulating hormone peptides (alpha-MSH), however they lack specificity and cause many "off-target" side effects.

Key Points: 
  • Companies like Clinuvel and Palatin have commercialized medical products using alpha-melanocortin stimulating hormone peptides (alpha-MSH), however they lack specificity and cause many "off-target" side effects.
  • ANEW's gamma-melanocortin stimulating hormones peptides (gamma-MSH) are highly selective and do not exhibit these side effects.
  • ANEW MEDICAL ACQUISITION CORP. is a technology and medical product asset holding company focused on the commercialization of essential medicines for life.
  • ANEW MEDICAL assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise.

Edsembli Achieves Certification with Ed-Fi Data Standard

Retrieved on: 
Thursday, January 19, 2023
LEAS, Certification, Information, Student, Education, School, Medicine

RALEIGH, N.C., Jan. 19, 2023 /PRNewswire/ - Edsembli , a leading provider of student information systems in North America, is proud to announce its certification with the Ed-Fi Data Standard.

Key Points: 
  • RALEIGH, N.C., Jan. 19, 2023 /PRNewswire/ - Edsembli , a leading provider of student information systems in North America, is proud to announce its certification with the Ed-Fi Data Standard.
  • This certification recognizes Edsembli's expertise in using the Ed-Fi Data Standard and tools to improve the accuracy, efficiency, and effectiveness of education data systems.
  • By achieving certification with the Ed-Fi Data Standard, Edsembli demonstrates its commitment to using these standards and tools to support local education agencies (LEAs) in improving their education data systems and driving better student outcomes.
  • "We are thrilled to have achieved certification with the Ed-Fi Data Standard," said Randy Lenaghan, CEO of Edsembli.

ANEW MEDICAL, INC. to Present at the Emerging Growth Conference on Wednesday, 01/11/23

Retrieved on: 
Monday, January 9, 2023
LEAS, Growth, Conference, OTC, INC, Life

NEW YORK, Jan. 9, 2023 /PRNewswire/ -- ANEW MEDICAL, INC (OTC:LEAS), focused on developing Essential Medicines for Life (ANEW MEDICAL or the "Company") is pleased to announce that it has been invited to present at the Emerging Growth Conference on Wednesday, January 11, 2023.

Key Points: 
  • NEW YORK, Jan. 9, 2023 /PRNewswire/ -- ANEW MEDICAL, INC (OTC:LEAS), focused on developing Essential Medicines for Life (ANEW MEDICAL or the "Company") is pleased to announce that it has been invited to present at the Emerging Growth Conference on Wednesday, January 11, 2023.
  • Dr. Sinkule will provide an overview of the Company's α-Klotho protein and genetic therapy programs and open the floor for questions.
  • ANEW MEDICAL will be presenting a briefing on the Company starting at 11:25 AM Eastern time in a virtual setting.
  • Register with Emerging Growth Conference to ensure you are able to attend the conference and receive any updates.

ANEW MEDICAL, INC. Acquires World Wide License to Treat Neurodegenerative Diseases Using a Longevity Protein and Gene Therapy Programs.

Retrieved on: 
Wednesday, December 7, 2022
Therapy, Neurodegeneration, AAV, Waste, OTC, Chromosome, Alzheimer's disease, Amyotrophic lateral sclerosis, UAB, Protein, Metabolism, Patient, DNA, Cancer, Heart failure, Mammal, Research, Longevity, Disease, Degenerative disease, ALS, Drug development, Cell nucleus, COVID-19, Cell, Human, Ageing, LEAS, Statement, Clotho, Parkinson's disease, RNA, Chronic kidney disease, Pharmaceutical industry, Vaccine

The Klotho gene was first identified in 1997 in humans and mammals and works as a humoral factor or hormone that may regulate aging and age-related protein function and senescence (cell aging).

Key Points: 
  • The Klotho gene was first identified in 1997 in humans and mammals and works as a humoral factor or hormone that may regulate aging and age-related protein function and senescence (cell aging).
  • Our Klotho gene therapy is a unique approach to treating ALS.
  • The therapeutic results generated in experimental animal models of ALS offers great promise for patients afflicted with the disease.
  • Other neurodegenerative diseases will utilize a tissue-specific promoter, a secreted-Klotho gene variant called s-KL, and adeno-associated virus (AAV) or lipid particles to deliver the gene inside a patient's cells.

ANEW MEDICAL, INC. To Present at Investor Summit Group's Q4 Conference

Retrieved on: 
Monday, November 7, 2022
Consumer, Sheraton New York Times Square Hotel, LEAS, Founder, Complimentary, OTC Markets Group, Investor, Conference, Real estate, Seventh Avenue, 1X1=1 (To Be One), CEO, Risk, Person, Laboratory, Cancer, Communication services sector reshuffle, Security (finance), Financial services, Technology, Klotho, Health care, Finance

New York, New York--(Newsfile Corp. - November 7, 2022) - ANEW MEDICAL, INC., (OTC Pink: LEAS), today announced that they will be attending the Q4 Investor Summit live in NYC at the Sheraton Times Square.

Key Points: 
  • New York, New York--(Newsfile Corp. - November 7, 2022) - ANEW MEDICAL, INC., (OTC Pink: LEAS), today announced that they will be attending the Q4 Investor Summit live in NYC at the Sheraton Times Square.
  • Location: Sheraton New York Times Square Hotel, 811 7th Avenue, W 53rd St, New York, NY 10019
    1x1s will be available for qualified investors.
  • The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.
  • The Q4 Investor Summit will take place in-person and virtually, featuring 50+ companies and over 300 investors comprised of institutional investors, family offices, and high net worth investors.

Police Transparency Solution Adopted by More Than 20% of California Law Enforcement Agencies

Retrieved on: 
Tuesday, November 1, 2022
Data Management, Technology, Law Enforcement, Emergency Services, Apps, Applications, Software, Artificial Intelligence, Networks, Audio, Video, Internet, Public Policy, Government, Mobile, Wireless, Growth, Trust, News, Legislation, Efficiency, SEC, Organization, Intelligence, Bakersfield, California, Industry, Program, Urszula Gacek, Data management, AI, Terminology, Assembly, Identity, Technology, Adoption, Bakersfield Police Department, NASDAQ, Compliance, Enterprise, Web browser, LEAS, Contact, Artificial intelligence, Tablet, LEA, RIPA, Solution, Mobile phone, Risk management, Veritone

This means officers are able to devote more time to patrolling and keeping communities safe, which is a top priority for citizens.

Key Points: 
  • This means officers are able to devote more time to patrolling and keeping communities safe, which is a top priority for citizens.
  • Veritone Contact addresses the publics call for greater transparency while providing law enforcement with tools that help ensure the legal rights of citizens are upheld and meet the obligations of new legislation.
  • A number of law enforcement agencies weighed in on the value and benefits that Veritone Contact has delivered to their force.
  • - Sergeant Daniel McClive, Bakersfield Police Department
    North Carolina became the first state in the U.S. to enact a law requiring law enforcement agencies to collect data on all routine traffic stops in 1999.

ANEW MEDICAL, INC. Acquires Five Drug Approvals with Manufacturing in Europe

Retrieved on: 
Tuesday, October 4, 2022
Financial Services and Markets Authority (Belgium), Cost Plus World Market, Cancer, News, Adult, Alzheimer's disease, Drug Quality and Security Act, CEO, Longevity, Ageing, U.S. Securities and Exchange Commission, Sale, FOLFIRI, Security (finance), LEAS, Neurodegeneration, MA, Founder, Securities Act of 1933, Marketing, Company, Pharmaceutical industry

NEW YORK, Oct. 4, 2022 /PRNewswire/ -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (OTCPK: LEAS) announced that it has acquired five market-approved anti-cancer drugs approved for sale in Germany.

Key Points: 
  • NEW YORK, Oct. 4, 2022 /PRNewswire/ -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (OTCPK: LEAS) announced that it has acquired five market-approved anti-cancer drugs approved for sale in Germany.
  • The drugs are important in the treatment of many solid tumors in both childhood and adult cancers.
  • He also added that, "Having a European manufacturing source for each of the five MA's was also important to us."
  • The prices of our products are, therefore, affordable even in this era of significantly increased energy prices in Europe.